Would you treat the prostate in a patient with widely metastatic disease who has CR to all metastatic sites after systemic therapy or ADT?  

This is an interesting hypothesis, but requires further study before offering. The trials that define a benefit to prostate RT in the metastatic setting (HORRAD, STAMPEDE, and now PEACE-1) did not use response-adapted selection criteria. Therefore, we cannot say that radiation to the prostate in an ...

Increasing clinical, molecular, and genetic evidence suggests that local therapy of the primary tumor may impact outcomes in patients presenting with metastatic prostate cancer. There are prospective data demonstrating improved outcomes for multimodal treatment of locally advanced prostate cancer an...